1.46  0.08 (5.8%)		10-24 16:00
Open: 1.39 High: 1.46 Volume: 1,652,383		Pre. Close: 1.38 Low: 1.385 Market Cap: 87(M)

Short term
Mid term
Targets	6-month :	2.75	1-year :	3.49
Resists	First :	2.35	Second :	2.99
Pivot price	1.68
Supports	First :	1.34	Second :	1.11
MAs	MA(5) :	1.49	MA(20) :	1.78
	MA(100) :	1.89	MA(250) :	3.14
MACD	MACD :	-0.2	Signal :	-0.1
%K %D	K(14,3) :	3.7	D(3) :	5
RSI	RSI(14): 39.2
52-week	High :	12.85	Low :	1.29

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ BMEA ] has closed above bottom band by 31.1%. Bollinger Bands are 47.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	1.46 - 1.47	1.47 - 1.48
Low:	1.36 - 1.37	1.37 - 1.38
Close:	1.44 - 1.46	1.46 - 1.47

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Tue, 21 Oct 2025
Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series - GlobeNewswire

Wed, 08 Oct 2025
Why Biomea Fusion (BMEA) Is Up on Promising Phase II Diabetes Data and What It Could Mean Next - simplywall.st

Wed, 08 Oct 2025
Why Biomea Fusion (BMEA) Is Up After Positive Diabetes Data and $25M Equity Raise – And What’s Next - Yahoo Finance

Tue, 07 Oct 2025
$25M Offering: Biomea Fusion Prices 11.2M Shares & Warrants at $2.05 — Closing Oct 8, 2025 - Stock Titan

Tue, 07 Oct 2025
Biomea Fusion prices $25 million public offering of shares and warrants - Investing.com

Tue, 07 Oct 2025
Biomea Fusion: Surging On Data, Sinking On Funding - I'm On The Sidelines - Seeking Alpha

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	71 (M)
Shares Float	49 (M)
Held by Insiders	8.1 (%)
Held by Institutions	41.5 (%)
Shares Short	7,750 (K)
Shares Short P.Month	8,050 (K)

EPS	-3
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.46
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-68.8 %
Return on Equity (ttm)	-170.6 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.61
Qtrly Earnings Growth	0 %
Operating Cash Flow	-100 (M)
Levered Free Cash Flow	-66 (M)

PE Ratio	-0.49
PEG Ratio	0
Price to Book value	3.1
Price to Sales	0
Price to Cash Flow	-1.04

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.